27 January 2009 Business
Industry news, February 2009
Merck & Co has agreed to pay $688 million (£445 million) to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin).
The case against the company was brought by a group of disgruntled investors, who claim Merck unfairly withheld negative information about the brands for a year.
In March 2008, Merck and Schering-Plough – which later merged under the Merck banner – published results of a key Vytorin trial that showed the drug did not work as well as expected. In the immediate aftermath, the share prices for the two dropped sharply. But the investors claim that the two companies knew that the trial was a flop at least a year before that.
The company will now pay $215 million to resolve the case against Merck and $473 million to resolve the case against Schering-Plough. However, it made no admission of wrongdoing and says that both companies acted responsibly in relation to the trial.
26 August 2014 Research
An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...
Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...
Current recycling procedure may do more harm than good